Approval · Notice of Compliance 13167 · 2012
CO RIZATRIPTAN: Notice of Compliance 13167
Issued March 30, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13167
- Date
- March 30, 2012
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CO RIZATRIPTAN | 02381699 | Approved |
| CO RIZATRIPTAN | 02381702 | Marketed |
Medicinal ingredients
- RIZATRIPTAN 5 MG per TAB
- RIZATRIPTAN 10 MG per TAB